SG11201405954YA - Treatment of brain cancer - Google Patents

Treatment of brain cancer

Info

Publication number: SG11201405954YA
Authority: SG; Singapore
Prior art keywords: treatment; brain cancer; brain; cancer
Prior art date: 2012-03-23

Application number

SG11201405954YA

Other languages

English (en)

Inventor

Patrice A Lee

Shannon L Winski

Kevin Koch

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-23

Filing date

2013-03-25

Publication date

2014-10-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201405954Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-25 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2014-10-30 Publication of SG11201405954YA publication Critical patent/SG11201405954YA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

SG11201405954YA 2012-03-23 2013-03-25 Treatment of brain cancer SG11201405954YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261615082P	2012-03-23	2012-03-23
PCT/US2013/033751 WO2013142875A1 (en)	2012-03-23	2013-03-25	Treatment of brain cancer

Publications (1)

Publication Number	Publication Date
SG11201405954YA true SG11201405954YA (en)	2014-10-30

Family

ID=48048296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201405954YA SG11201405954YA (en)	2012-03-23	2013-03-25	Treatment of brain cancer

Country Status (30)

Country	Link
US (3)	US20150110780A1 (el)
EP (4)	EP3400943B1 (el)
JP (6)	JP2015514075A (el)
KR (3)	KR102317166B1 (el)
CN (2)	CN104203279B (el)
AU (4)	AU2013234921A1 (el)
CA (1)	CA2867723C (el)
CL (1)	CL2014002497A1 (el)
CO (1)	CO7071139A2 (el)
CY (2)	CY1120204T1 (el)
DK (2)	DK2827900T3 (el)
ES (2)	ES2855142T3 (el)
HK (1)	HK1206276A1 (el)
HR (1)	HRP20180659T1 (el)
HU (2)	HUE053156T2 (el)
IL (3)	IL234627B (el)
LT (1)	LT2827900T (el)
MX (1)	MX354024B (el)
MY (2)	MY174883A (el)
NZ (4)	NZ756264A (el)
PH (1)	PH12014502032A1 (el)
PL (2)	PL3400943T3 (el)
PT (2)	PT3400943T (el)
RS (1)	RS57140B1 (el)
RU (2)	RU2672575C2 (el)
SG (1)	SG11201405954YA (el)
SI (2)	SI2827900T1 (el)
TR (1)	TR201808450T4 (el)
UA (1)	UA122044C2 (el)
WO (1)	WO2013142875A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE035247T2 (hu)	2011-10-14	2018-05-02	Array Biopharma Inc	Szilárd diszperzió
EP2766363A1 (en)	2011-10-14	2014-08-20	Array Biopharma, Inc.	Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
ES2855142T3 (es)	2012-03-23	2021-09-23	Array Biopharma Inc	Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+
CA3055957A1 (en) *	2017-03-09	2018-09-13	The Board Of Trustees Of The Leland Stanford Junior University	Treatment of pediatric brain tumors with targeting of cd47 pathway
EP3615067A1 (en)	2017-04-28	2020-03-04	Seattle Genetics, Inc.	Treatment of her2 positive cancers
WO2019197973A1 (en) *	2018-04-09	2019-10-17	Moshe Giladi	Treating tumors with ttfields and an aurora kinase inhibitor
CN109942576B (zh) *	2019-03-07	2020-09-11	上海工程技术大学	Irbinitinib及中间体的制备方法
CN111825604A (zh) *	2019-04-16	2020-10-27	宁波药腾医药科技有限公司	一种图卡替尼及其中间产物的合成方法
MX2022001863A (es)	2019-08-12	2022-05-30	Deciphera Pharmaceuticals Llc	Metodos para tratar los tumores del estroma gastrointestinal.
AU2020417282B2 (en)	2019-12-30	2023-08-31	Deciphera Pharmaceuticals, Llc	Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
PL4084778T3 (pl)	2019-12-30	2024-03-04	Deciphera Pharmaceuticals, Llc	Formulacje amorficznych inhibitorów kinazy i sposoby ich zastosowania

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH690163A5 (fr) *	1995-07-28	2000-05-31	Symphar Sa	Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) *	1998-09-22	2002-02-26	Hoffmann-La Roche Inc.	Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) *	2000-01-21	2005-07-10	Чилдренз Хоспитал Лос-Анджелес	Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en)	2000-05-30	2002-09-26	Gewirtz David A.	Combination of radiation and vitamin D3 analogs for the treatment of cancer
CN103772373B (zh)	2003-08-14	2017-06-09	阿雷生物药品公司	作为受体酪氨酸激酶抑制剂的喹唑啉类似物
BRPI0511754A (pt)	2004-06-03	2008-01-02	Smithkline Beechman Cork Ltd	uso de um composto ou sais ou solvatos do mesmo
CN1989112A (zh) *	2004-06-03	2007-06-27	史密丝克莱恩比彻姆（科克）有限公司	癌症治疗方法
BR122018075851B1 (pt)	2005-11-15	2022-01-11	Array Biopharma Inc	Compostos relacionados ao tratamento de doença hiperproliferativa e processos para preparar compostos
JP5068270B2 (ja)	2006-01-31	2012-11-07	ノバルティスアーゲー	癌を処置するためのｉｌ−１７アンタゴニスト抗体
JP2010540460A (ja) *	2007-09-24	2010-12-24	トラガラファーマシューティカルズ，インク．	ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
EP3692988A3 (en)	2008-03-18	2020-10-14	Genentech, Inc.	Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
EP2766363A1 (en)	2011-10-14	2014-08-20	Array Biopharma, Inc.	Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
HUE035247T2 (hu)	2011-10-14	2018-05-02	Array Biopharma Inc	Szilárd diszperzió
ES2855142T3 (es)	2012-03-23	2021-09-23	Array Biopharma Inc	Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+

2013
- 2013-03-25 ES ES18162971T patent/ES2855142T3/es active Active
- 2013-03-25 HU HUE18162971A patent/HUE053156T2/hu unknown
- 2013-03-25 MY MYPI2014702686A patent/MY174883A/en unknown
- 2013-03-25 NZ NZ756264A patent/NZ756264A/en unknown
- 2013-03-25 MX MX2014011437A patent/MX354024B/es active IP Right Grant
- 2013-03-25 KR KR1020207027176A patent/KR102317166B1/ko active IP Right Grant
- 2013-03-25 RS RS20180484A patent/RS57140B1/sr unknown
- 2013-03-25 KR KR1020147029340A patent/KR102160462B1/ko active IP Right Grant
- 2013-03-25 PT PT181629718T patent/PT3400943T/pt unknown
- 2013-03-25 RU RU2014142700A patent/RU2672575C2/ru active
- 2013-03-25 PT PT137144978T patent/PT2827900T/pt unknown
- 2013-03-25 ES ES13714497.8T patent/ES2673165T3/es active Active
- 2013-03-25 LT LTEP13714497.8T patent/LT2827900T/lt unknown
- 2013-03-25 WO PCT/US2013/033751 patent/WO2013142875A1/en active Application Filing
- 2013-03-25 NZ NZ74161513A patent/NZ741615A/en unknown
- 2013-03-25 DK DK13714497.8T patent/DK2827900T3/en active
- 2013-03-25 EP EP18162971.8A patent/EP3400943B1/en active Active
- 2013-03-25 EP EP13714497.8A patent/EP2827900B1/en active Active
- 2013-03-25 JP JP2015501952A patent/JP2015514075A/ja active Pending
- 2013-03-25 PL PL18162971T patent/PL3400943T3/pl unknown
- 2013-03-25 HU HUE13714497A patent/HUE037966T2/hu unknown
- 2013-03-25 CN CN201380015856.XA patent/CN104203279B/zh active Active
- 2013-03-25 EP EP23163332.2A patent/EP4252855A3/en active Pending
- 2013-03-25 PL PL13714497T patent/PL2827900T3/pl unknown
- 2013-03-25 UA UAA201411479A patent/UA122044C2/uk unknown
- 2013-03-25 EP EP20210661.3A patent/EP3842044A1/en not_active Withdrawn
- 2013-03-25 RU RU2018138976A patent/RU2018138976A/ru unknown
- 2013-03-25 SI SI201331019T patent/SI2827900T1/en unknown
- 2013-03-25 CN CN201811150918.9A patent/CN109223791A/zh active Pending
- 2013-03-25 US US14/387,533 patent/US20150110780A1/en not_active Abandoned
- 2013-03-25 NZ NZ724544A patent/NZ724544A/en unknown
- 2013-03-25 KR KR1020217033686A patent/KR102490961B1/ko active IP Right Grant
- 2013-03-25 TR TR2018/08450T patent/TR201808450T4/tr unknown
- 2013-03-25 AU AU2013234921A patent/AU2013234921A1/en not_active Abandoned
- 2013-03-25 CA CA2867723A patent/CA2867723C/en active Active
- 2013-03-25 SI SI201331844T patent/SI3400943T1/sl unknown
- 2013-03-25 SG SG11201405954YA patent/SG11201405954YA/en unknown
- 2013-03-25 NZ NZ630843A patent/NZ630843A/en unknown
- 2013-03-25 DK DK18162971.8T patent/DK3400943T3/da active
- 2013-03-25 MY MYPI2019003395A patent/MY202114A/en unknown
2014
- 2014-09-12 PH PH12014502032A patent/PH12014502032A1/en unknown
- 2014-09-14 IL IL234627A patent/IL234627B/en active IP Right Grant
- 2014-09-19 CO CO14208829A patent/CO7071139A2/es unknown
- 2014-09-22 CL CL2014002497A patent/CL2014002497A1/es unknown
2015
- 2015-07-23 HK HK15107019.5A patent/HK1206276A1/xx unknown
2017
- 2017-05-25 JP JP2017103957A patent/JP2017141302A/ja active Pending
- 2017-12-06 AU AU2017272232A patent/AU2017272232C1/en active Active
2018
- 2018-04-25 HR HRP20180659TT patent/HRP20180659T1/hr unknown
- 2018-05-14 CY CY20181100493T patent/CY1120204T1/el unknown
- 2018-09-06 IL IL261659A patent/IL261659A/en unknown
2019
- 2019-02-27 JP JP2019034250A patent/JP6898960B2/ja active Active
- 2019-05-02 US US16/402,068 patent/US11504370B2/en active Active
- 2019-05-23 AU AU2019203618A patent/AU2019203618B2/en active Active
- 2019-09-09 IL IL269205A patent/IL269205B/en active IP Right Grant
2021
- 2021-02-16 CY CY20211100126T patent/CY1123837T1/el unknown
- 2021-06-11 JP JP2021097676A patent/JP2021178820A/ja active Pending
- 2021-11-01 AU AU2021261849A patent/AU2021261849A1/en not_active Abandoned
2022
- 2022-10-28 US US17/975,709 patent/US20230190749A1/en active Pending
- 2022-11-04 JP JP2022177278A patent/JP7404485B2/ja active Active
2023
- 2023-12-13 JP JP2023209972A patent/JP2024019526A/ja active Pending

Also Published As

Publication number	Publication date
ES2673165T3 (es)	2018-06-20
DK2827900T3 (en)	2018-05-07
IL261659A (en)	2018-10-31
KR102490961B1 (ko)	2023-01-19
MY174883A (en)	2020-05-20
HK1206276A1 (en)	2016-01-08
PT2827900T (pt)	2018-06-14
PL2827900T3 (pl)	2018-08-31
NZ630843A (en)	2017-01-27
NZ756264A (en)	2022-09-30
JP2017141302A (ja)	2017-08-17
DK3400943T3 (da)	2021-02-08
WO2013142875A1 (en)	2013-09-26
IL269205B (en)	2020-06-30
HUE053156T2 (hu)	2021-06-28
CA2867723C (en)	2022-11-08
EP4252855A3 (en)	2023-11-15
KR20140139009A (ko)	2014-12-04
EP2827900A1 (en)	2015-01-28
JP2015514075A (ja)	2015-05-18
JP2024019526A (ja)	2024-02-09
IL234627B (en)	2018-10-31
TR201808450T4 (tr)	2018-07-23
PT3400943T (pt)	2021-02-02
JP2019081792A (ja)	2019-05-30
PH12014502032A1 (en)	2014-11-24
HUE037966T2 (hu)	2018-09-28
JP2022190126A (ja)	2022-12-22
KR102317166B1 (ko)	2021-10-26
JP2021178820A (ja)	2021-11-18
KR20210131426A (ko)	2021-11-02
RU2014142700A (ru)	2016-05-20
EP4252855A2 (en)	2023-10-04
AU2021261849A1 (en)	2021-12-02
SI3400943T1 (sl)	2021-03-31
JP7404485B2 (ja)	2023-12-25
CY1120204T1 (el)	2018-12-12
RU2018138976A3 (el)	2022-04-08
LT2827900T (lt)	2018-05-10
PL3400943T3 (pl)	2021-06-14
CA2867723A1 (en)	2013-09-26
EP3400943A1 (en)	2018-11-14
CN104203279A (zh)	2014-12-10
MX354024B (es)	2018-02-08
CN109223791A (zh)	2019-01-18
CL2014002497A1 (es)	2014-11-14
AU2017272232A1 (en)	2018-01-04
US20230190749A1 (en)	2023-06-22
KR20200115656A (ko)	2020-10-07
KR102160462B1 (ko)	2020-09-28
UA122044C2 (uk)	2020-09-10
NZ741615A (en)	2019-10-25
US20150110780A1 (en)	2015-04-23
CY1123837T1 (el)	2022-05-27
MY202114A (en)	2024-04-04
CO7071139A2 (es)	2014-09-30
AU2013234921A1 (en)	2014-10-02
RU2018138976A (ru)	2018-12-06
ES2855142T3 (es)	2021-09-23
AU2017272232C1 (en)	2019-08-15
EP3842044A1 (en)	2021-06-30
US20190255051A1 (en)	2019-08-22
HRP20180659T1 (hr)	2018-06-01
AU2017272232B2 (en)	2019-02-28
US11504370B2 (en)	2022-11-22
EP3400943B1 (en)	2020-12-02
AU2019203618B2 (en)	2021-08-05
RS57140B1 (sr)	2018-07-31
MX2014011437A (es)	2014-11-10
NZ724544A (en)	2018-05-25
AU2019203618A1 (en)	2019-06-13
EP2827900B1 (en)	2018-03-21
JP6898960B2 (ja)	2021-07-07
CN104203279B (zh)	2018-10-30
IL269205A (en)	2019-11-28
RU2672575C2 (ru)	2018-11-16
SI2827900T1 (en)	2018-06-29

Publication	Publication Date	Title
IL288181A (en)	2022-01-01	Cancer treatment methods
IL267242B (en)	2020-08-31	Cancer treatment
IL261659A (en)	2018-10-31	Brain cancer treatment
HK1214128A1 (zh)	2016-07-22	癌症的治療
HK1205254A1 (en)	2015-12-11	Methods of treatment of cancer
GB201217892D0 (en)	2012-11-21	Treatment of cancer
HK1204956A1 (en)	2015-12-11	Treatment of cancer
HK1210023A1 (en)	2016-04-15	Cancer treatment
SI2892925T1 (sl)	2020-11-30	Kombinacijsko zdravljenje raka
PL2855475T3 (pl)	2018-02-28	Alfa-karboliny do leczenia nowotworu
IL237229A0 (en)	2015-04-30	Methods of treating cancer using lipoplatin
GB201217890D0 (en)	2012-11-21	Treatment of cancer
GB201222563D0 (en)	2013-01-30	Cancer treatment
GB201208296D0 (en)	2012-06-20	Treatment of cancer
GB201222949D0 (en)	2013-01-30	Combination Treatment of Cancer
GB201222950D0 (en)	2013-01-30	Combination treatment of cancer
GB201221118D0 (en)	2013-01-09	Methods of treatment
GB201216748D0 (en)	2012-10-31	Methods of treatment
GB201216740D0 (en)	2012-10-31	Methods of treatment
GB201206325D0 (en)	2012-05-23	Methods of treatment
GB201206326D0 (en)	2012-05-23	Methods of treatment
GB201206330D0 (en)	2012-05-23	Methods of treatment
GB201206324D0 (en)	2012-05-23	Methods of treatment